» Articles » PMID: 32816858

A Division of Labor Between YAP and TAZ in Non-Small Cell Lung Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2020 Aug 21
PMID 32816858
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. The paralogous transcriptional cofactors Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also called WWTR1), the main downstream effectors of the Hippo signal transduction pathway, are emerging as pivotal determinants of malignancy in lung cancer. Traditionally, studies have tended to consider YAP and TAZ as functionally redundant transcriptional cofactors with similar biological impact. However, there is growing evidence that each of them also possesses distinct attributes. Here we sought to systematically characterize the division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common histological subtype of lung cancer. Representative NSCLC cell lines as well as patient-derived data showed that the two paralogs orchestrated nonoverlapping transcriptional programs in this cancer type. YAP preferentially regulated gene sets associated with cell division and cell-cycle progression, whereas TAZ preferentially regulated genes associated with extracellular matrix organization. Depletion of resulted in growth arrest, whereas its overexpression promoted cell proliferation. Likewise, depletion of compromised cell migration, whereas its overexpression enhanced migration. The differential effects of YAP and TAZ on key cellular processes were also associated with differential response to anticancer therapies. Uncovering the different activities and downstream effects of YAP and TAZ may thus facilitate better stratification of patients with lung cancer for anticancer therapies. SIGNIFICANCE: Thease findings show that oncogenic paralogs YAP and TAZ have distinct roles in NSCLC and are associated with differential response to anticancer drugs, knowledge that may assist lung cancer therapy decisions.

Citing Articles

YAP as a potential therapeutic target for myofibroblast formation in asthma.

Guo Y, Zhou Y, Wang R, Lin Y, Lan H, Li Y Respir Res. 2025; 26(1):51.

PMID: 39939959 PMC: 11823061. DOI: 10.1186/s12931-025-03115-x.


Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management.

Bruno T, Catena V, Blandino G, Fanciulli M, Di Agostino S J Exp Clin Cancer Res. 2024; 43(1):322.

PMID: 39695699 PMC: 11653552. DOI: 10.1186/s13046-024-03248-9.


PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State.

Killarney S, Mesa G, Washart R, Mayro B, Dillon K, Wardell S Cancer Discov. 2024; 15(3):595-615.

PMID: 39560431 PMC: 11875962. DOI: 10.1158/2159-8290.CD-24-0928.


Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.

Sharma R, Sharma S, Shriwas P, Mehta L, Vu A, Mouw J iScience. 2024; 27(11):111133.

PMID: 39524367 PMC: 11544388. DOI: 10.1016/j.isci.2024.111133.


The oncogenic axis YAP/MYC/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity.

Lo Sardo F, Turco C, Messina B, Sacconi A, Auciello F, Pulito C Cell Death Discov. 2024; 10(1):452.

PMID: 39455556 PMC: 11511861. DOI: 10.1038/s41420-024-02216-8.


References
1.
Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

2.
Arandkar S, Furth N, Elisha Y, Nataraj N, van der Kuip H, Yarden Y . Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proc Natl Acad Sci U S A. 2018; 115(25):6410-6415. PMC: 6016816. DOI: 10.1073/pnas.1719076115. View

3.
Blecher-Gonen R, Barnett-Itzhaki Z, Jaitin D, Amann-Zalcenstein D, Lara-Astiaso D, Amit I . High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. Nat Protoc. 2013; 8(3):539-54. DOI: 10.1038/nprot.2013.023. View

4.
Gao Y, Zhang W, Han X, Li F, Wang X, Wang R . YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun. 2014; 5:4629. DOI: 10.1038/ncomms5629. View

5.
Gobbi G, Donati B, Faria do Valle I, Reggiani F, Torricelli F, Remondini D . The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 2019; 38(42):6801-6817. DOI: 10.1038/s41388-019-0924-1. View